TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06466603

Intervention type: DIETARY_SUPPLEMENT
Intervention: GABA Probiotic Dose 1
Description: Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.

Intervention type: DIETARY_SUPPLEMENT
Intervention: GABA Probiotic Dose 2
Description: Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Placebo Group
Description: Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
Study: NCT05496231

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV9 High formulation
Description: 3 doses of a high formulation investigational adjuvanted HPV9 vaccine intramuscularly (IM) on Day 1, Month 2, and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV9 Medium formulation
Description: 3 doses of a medium formulation investigational adjuvanted HPV9 vaccine administered IM on Day 1, Month 2, and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV9 Low formulation
Description: 3 doses of a low formulation investigational adjuvanted HPV9 vaccine administered IM on Day 1, Month 2, and Month 6.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil 9
Description: 3 doses of the marketed HPV vaccine (Gradasil 9) administered IM on Day 1, Month 2, and Month 6.
Study: NCT05436444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Mallard/Ohio-99/MM4/1989 H10N7
Description: The human challenge virus will be administered intranasally to each participant using a nasal atomizer. A total volume of up to 2 mL will be administered split between both nostrils of each participant.
Study: NCT05130463

Intervention type: DRUG
Intervention: empagliflozin/linagliptin
Description: tablet
Study: NCT05478018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Supervised high-intensity interval training for 12 weeks three times per week
Study: NCT06324370

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Virgin Coconut Oil
Description: Virgin Coconut Oil (VCO) will be administered with 240 mL water and standardized food during dosing periods.While the participant is standing up, each dose will be administered orally with at least 240 mL of water and standardized meal after an overnight fast of at least 10 hours on each occasion. The time of dosing will be recorded to the nearest minute in the case report form (CRF).~No other liquid or solid food intake is permitted during this time. Fluid intake will be ad libitum 4 hours post-dose. There will be a washout interval of 7 days between the single- and multiple-dose studies.~Participants will not be permitted to take any prescribed medication or over-the-counter products (including vitamins and herbal supplements) within 14 days prior to dosing or during the course of the study.
Study: NCT06544148

Intervention type: DEVICE
Intervention: Electrical impedance tomography
Description: In addition to routine critical care with a pulmonary artery catheter already in place (PAC), an electrical impedance tomography (EIT) belt will be placed in patients enrolled in this study. Data will be analyzed offline and clinical trajectory and/or decisions will not be impacted by this additional monitoring. EIT is a non-invasive, safe, and radiation-free medical imaging modality.
Study: NCT05811637

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates Exercise
Description: The program will be applied with the Pilates exercises every week. All patients were evaluated before and after the treatment (6 weeks).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Rehabilitation
Description: The program will be applied with the progression of the supervised rehabilitation in the 4th week
Study: NCT05784597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-OncoFAP administration
Description: All patients will receive a single intravenous bolus administration of 250 MBq (225 - 275 MBq)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-OncoFAP administration
Description: All patients will receive a single intravenous bolus administration of 250 MBq (225 - 275 MBq)
Study: NCT03399773

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dilanubicel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspirate and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspirate and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT04769986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Mindfulness-Relapse Prevention (mMBRP)
Description: Mindfulness Coach 2.0 is a mobile application designed by the VA's National Center for PTSD. The app provides: (a) psychoeducational topics related to mindfulness; (b) audio-guided mindfulness exercises; (c) self-assessment using the Five Facet Mindfulness Questionnaire (d) a journal to track mindfulness practice sessions; (e) goal setting and tracking; (f) personal, customizable reminders; and (g) immediate access to support and crisis resources. We will enhance Mindfulness Coach with MBRP content by adding information about the triangle of awareness to understand connections among thoughts, sensations, and emotions, and specific meditations of sober breathing space and urge surfing to deal with cravings. We will add additional MBRP-specific modules. Participants will be asked to complete the intervention during 8 weeks, with two to three modules per week. After a beta test with 20 veterans, feedback will be used to refine the app for the national randomized clinical trial (RCT).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise/healthy eating mobile app
Description: Participants in the control condition will be asked to download an exercise/healthy eating mobile app and use it for 8 weeks. Similar to Mindfulness Coach, the app will have specialized self-management guides that follow a guide-per-week format, educational videos that teach diet and exercise strategies, and a diary to track diet and exercise progress.
Study: NCT06048705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3901961
Description: GSK3901961 was administered.
Study: NCT06141967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WITHINGS Sleep Analyzer
Description: Potentially eligible patients will be offered to participate in the study, the information leaflet will be given to them and the informed consent form will be signed if the patient agrees to participate in the study.~In hospitalization in Endocrinology:~* Realization of the current care report~* Including systematic achievement of EPWORTH and BERLIN scores~* Activation of the WSA throughout the duration of the hospitalization~* Completion of a feasibility questionnaire for the team~* Quantification of the non-usable screening technique~* Completion of a patient experience questionnaire at the end of the stay~* In the event of published positive criteria either for the BERLIN questionnaires, EPWORTH questionnaires or WSA, the patient will be referred to the VISAS center for definitive diagnostic evaluation by polygraphy or polysomnography.
Study: NCT06048705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide was administered as lymphodepleting chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine was administered as lymphodepleting chemotherapy.
Study: NCT06456541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Extensively Hydrolyzed Formula
Description: Experimental powder formula

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Extensively Hydrolyzed Formula
Description: Placebo powder formula
Study: NCT05302609

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SclerFIX
Description: Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical cord lining membrane allograft used as substitute for scleral graft in reinforcement of scleral thinning.
Study: NCT05931497

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: whole body hyperthermia
Description: heat will be applied to the participant through a sauna to increase core body temperature

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body hyperthermia
Description: heat will be applied to the participant through a sauna to increase core body temperature
Study: NCT06565663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MaPGAS Decision Aid
Description: This intervention involves a novel, web-based decision aid tool specifically designed to support transgender and non-binary individuals assigned female at birth in making informed decisions about Metoidioplasty and Phalloplasty Gender Affirming Surgeries (MaPGAS). The tool includes comprehensive information on surgical options, risks, benefits, and medical illustrations to aid in aligning surgical decisions with the individual's personal values and goals.
Study: NCT06530303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Tumor Infiltrating Lymphocytes (TIL) IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion
Study: NCT04736121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin microspheres containing yttrium-90 (Y-90)
Description: Biocompatible resin microspheres are an injectable permanent implant and preferentially placed into the distal microvascular supply of tumors to provide direct irradiation of tissue and destruction of the microvascular bed. Spheres contain yttrium-90 (Y-90) and are a size between 20 and 60 microns in diameter.
Study: NCT04575961

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles
Study: NCT05857878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1815368
Description: BI 1815368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1815368
Description: BI 1815368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1815368
Description: BI 1815368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1815368
Description: BI 1815368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1815368
Description: BI 1815368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1815368
Description: BI 1815368

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo
Study: NCT06171737

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: The American College of Cardiology decision aid: Treatment Options for Severe Aortic Stenosis for patients deciding between Tavi and Surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared Decision Making Skills Training
Description: 60-minute online training session that will provide practical tips, interactive case studies and tools for conducting shared decision making conversations covering core competencies
Study: NCT04636437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine 100 Mg
Description: Participants will receive 100 mg tablet by mouth daily with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine 100 Mg
Description: Participants will receive 100 mg tablet by mouth daily with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide/emtricitabine
Description: NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide/emtricitabine
Description: NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir alafenamide/lamivudine
Description: NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir alafenamide/lamivudine
Description: NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Integrase strand transfer inhibitors
Description: NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disproxil fumarate/emtricitabine
Description: NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disproxil fumarate/lamivudine
Description: NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
Study: NCT06035510

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein supplement
Description: Participants are given Isolated whey protein supplement in evening before surgery and first day of post operation to compare with standard operative care on postoperative outcomes after gynecological cancer surgery
Study: NCT05230407

Intervention type: OTHER
Intervention: Visual analog scale (VAS) assesment of pain
Description: Post operation VAS score will be assessed before discharge from hospital and 24 hours post operation
Study: NCT05861752

Intervention type: BEHAVIORAL
Intervention: Treatment as usual
Description: both groups will undergo a psychiatric assessment including interviews, impulsivity tests and fill out questionnaires and leave blood samples. The clinical population will be followed regarding treatment as usual
Study: NCT05385692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M02D1
Description: Administration by intravenous infusion
Study: NCT06541249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: MTX has recently been identified as a dose-dependent JAK/STAT pathway inhibitor. 15mg will be given once a week orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: MTX has recently been identified as a dose-dependent JAK/STAT pathway inhibitor. 15mg will be given once a week orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: MTX has recently been identified as a dose-dependent JAK/STAT pathway inhibitor. 15mg will be given once a week orally.
Study: NCT06466161

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upper Arm Cylindrical Blood Pressure Cuff
Description: In Group 1, the upper arm cylindrical cuff is inflated first, followed by inflation of the forearm conical cuff.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forearm Conical Blood Pressure Cuff
Description: In Group 2, the forearm conical cuff is inflated first, followed by inflation of the upper arm cylindrical cuff.
Study: NCT04012710

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy
Description: Conventional abdominal laparoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vNOTES
Description: Transvaginal natural orifice transluminal endoscopic surgery for salpingo-oophorectomy
Study: NCT06222294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: Loading dose: 0.08mg/kg Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1-0.2mg/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Medium and Long Chain Fat Emulsion Injection
Description: Loading dose: 0.3-0.5mg/kg Maintenance dose: IV Propofol Medium and Long Chain Fat Emulsion Injection, dose range 0.3-4.0mg/kg/h, increment or decrement of 0.3-0.6mg/kg/h
Study: NCT04839601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RNS System
Description: The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
Study: NCT05726383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iscador*P
Description: Iscador P given for 2 cycles with follow up imaging done every 2 cycles. If imaging is negative patient remains on study for 13 cycles. If new lesion is found, then patient is off study.
Study: NCT05802537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exergame program
Description: The home-based exergame program was conducted using the Nintendo Switch and Ring Fit Adventure program at participants' homes. The program included a 10-minute warm-up, 30 minutes of main exercise, and a 10-minute cool-down, lasting a total of 50 minutes per session. Sessions were held three times per week for eight weeks. The exercises targeted lower extremity strength, balance, and flexibility and included yoga, leg exercises (e.g., squats, knee lifts), and other activities performed in a gamified virtual environment. Participants received guidance on using the console, and family members were involved to support proper execution of the exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online education on fall prevention and musculoskeletal health management
Description: The online education intervention consisted of weekly sessions conducted for 50 minutes over an eight-week period, focusing on fall prevention and musculoskeletal health management. Participants joined the sessions via a video-conference platform. The content covered education on aging, musculoskeletal disorders, fall prevention strategies, and understanding falls and fractures. These sessions aimed to enhance participants' awareness and knowledge, thereby helping them adopt preventive behaviors.
Study: NCT05118529

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Mobilization to chair

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Mobilization to chair
Study: NCT05494697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rintatolimod
Description: Rintatolimod (poly I : poly C12U)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rintatolimod
Description: Rintatolimod (poly I : poly C12U)
Study: NCT06097585

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: case control study in which group will receive SGLT2I and group will not , to detect impact of the drug in changing NYHA class for heart failure and echographic parameter